Cerev­el notch­es Phase 3 Parkin­son's win ahead of Ab­b­Vie trans­ac­tion clos­ing

As it waits for its ac­qui­si­tion by Ab­b­Vie to fi­nal­ize, Cerev­el re­port­ed a Phase 3 win for one of its pro­grams in Parkin­son’s dis­ease. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.